

Article

Not peer-reviewed version

Leukotrienes E4 and B4 and Vascular Endothelium – New Insight into the Link between Vascular Inflammation and Peripheral Arterial Disease and Its Complications

[Agnieszka Wachsmann-Maga](#) , Aleksandra Włodarczyk , [Mikołaj Maga](#) ^{*} , [Krzysztof Batko](#) , Katarzyna Bogucka , [Maria Kapusta](#) , [Piotr Terlecki](#) , [Paweł Maga](#)

Posted Date: 8 May 2023

doi: 10.20944/preprints202305.0532.v1

Keywords: endothelium; leukotrienes; vascular inflammation; peripheral arterial disease



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Leukotrienes E4 and B4 and Vascular Endothelium – New Insight into the Link between Vascular Inflammation and Peripheral Arterial Disease and Its Complications

Agnieszka Wachsmann-Maga ^{1,2}, Aleksandra Włodarczyk ¹, Mikołaj Maga ^{2,3*}, Krzysztof Batko ⁴, Katarzyna Bogucka ², Maria Kapusta ⁵, Piotr Terlecki ⁶ and Paweł Maga ^{1,2}

¹ Department of Angiology, Medical Faculty, Jagiellonian University Medical College, Krakow, Poland

² Clinical Department of Angiology, University Hospital in Krakow, Poland

³ Department of Rehabilitation in Internal Medicine, Health Sciences Faculty, Jagiellonian University Medical College, Krakow, Poland

⁴ Department of Research and Design, Medicine Economy Law Society (MELS) Foundation, Krakow, Poland

⁵ Department of Diagnostics, Chair of Clinical Biochemistry, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland

⁶ Department of Vascular Surgery and Angiology, Medical University of Lublin, 20-081 Lublin, Poland

* Correspondence: Clinical Department of Angiology, University Hospital in Krakow, Poland

ul. Jakubowskiego 2, 30-688 Krakow, Poland; Mikołaj.maga@gmail.com; Tel: (0048) 12 400 30 00

Abstract: Leukotrienes are proinflammatory mediators that participate in the process of atherogenesis and contribute to the development of symptomatic peripheral arterial disease. The aim was to evaluate the relationship between leukotriene E4 (LTE4) and B4 (LTB4) with parameters reflecting endothelial vascular function in patients with chronic lower limb ischemia. This prospective observational study enrolled 50 consecutive patients undergoing endovascular treatment due to chronic lower limb ischemia (Rutherford 3). All participants were followed-up for one year (after 1, 3, 6 and 12 months), with a sequential assessment of urinary LTE4 and LTB4, as well as measures of endothelial and vascular function: Flow-Mediated Dilatation (FMD), Intima-Media Thickness (IMT), corrected Augmentation Index (AI75), Shear Rate (SR), Ankle-Brachial Index (ABI), Toe-Brachial Index (TBI). There was a significant relationship between LTE4 and measures of vascular function: FMD ($R^2 = 0.69$, $P < 0.001$), IMT ($R^2 = 0.12$, $P < 0.01$), AI75 ($R^2 = 0.43$, $P < 0.001$), SR ($R^2 = 0.48$, $P < 0.001$). Similar findings were noted for LTB4: FMD ($R^2 = 0.47$, $p < 0.001$), IMT ($R^2 = 0.23$, $P < 0.001$), AI75 ($R^2 = 0.61$, $P < 0.001$) and SR ($R^2 = 0.33$, $P < 0.001$). Alterations in parameters were significantly related: Δ LTE4 vs Δ FMD ($R^2 = 0.63$, $P < 0.001$), Δ SR ($R^2 = 0.42$, $P < 0.001$) and Δ LTB4 vs AI75 ($R^2 = 0.40$, $P < 0.001$), SR ($R^2 = 0.29$, $P < 0.001$). We conclude, that increasing concentrations of LTE4 and LTB4 are associated with impairment of vascular and endothelial function, which may lead to worse endovascular treatment clinical outcomes.

Keywords: endothelium; leukotrienes; vascular inflammation; peripheral arterial disease

1. Introduction

Acute manifestations of atherosclerosis remain the most common cause of premature death, yet the mechanisms shaping this process are still not fully understood [1]. Even though the inflammatory component of atherogenesis has gained the attention of researchers over recent years, multiple hypotheses still exist regarding the molecular interplay, which drives arterial inflammation and accelerates plaque creation [2,3]. An array of recent data suggests that anti-inflammatory therapy may be of added benefit in the treatment of coronary artery disease, though efficacy in the treatment of peripheral disease is uncertain [4,5].

The inner layer of arteries is composed of the endothelium, which plays the role of an interface between molecules circulating in blood and cells residing within the vessel wall. Impairment of its proper function is assumed to be the origin point for atherosclerotic processes and is incited by a pro-inflammatory milieu [6].

Leukotrienes (LT) are lipid molecules, which exert multiple physiologic functions within the vasculature and organ systems, also being crucial mediators in the initial stages of inflammation. Throughout the process of atherogenesis, the abundance of pro-inflammatory signals also contributes to the development of unstable plaques.

Recent data from Sweden suggests that asthmatic patients treated with leukotriene receptor antagonists are less vulnerable to cardiovascular disease [7]. Studies in acute coronary syndrome report a reduction in LT levels by 12 weeks, with significant differences observed for the incidence of atherosclerotic plaques and plaque volume [8]. The link between LTs and atherosclerosis has been shown to have a genetic component [9].

The clinical utility of arachidonic acid metabolites as biomarkers of peripheral vascular disease remains not fully explored. In patients with intermittent claudication, the occurrence of restenosis after endovascular treatment was related to urinary leukotriene E4 (LTE4) concentration, while perioperative thromboxane B2 levels were tied to the rate of major adverse cardiovascular events [10,11]. A comprehensive literature review was recently conducted to examine the association between elevated LT and the presence of atherosclerotic disease, showing the existing dependence, but not answering the question of its mechanism [12].

While the role of LT as mediators has been established in the process of atherogenesis, the relationship with endothelial function and vascular measures is not fully known. To our knowledge, the relationship between LT concentrations and alterations in endothelial function have not been studied prospectively in the context of peripheral arterial disease.

2. Materials and Methods

The Materials and Methods should be described with sufficient details to allow others to replicate and build on the published results. Please note that the publication of your manuscript implicates that you must make all materials, data, computer code, and protocols associated with the publication available to readers. Please disclose at the submission stage any restrictions on the availability of materials or information. New methods and protocols should be described in detail while well-established methods can be briefly described and appropriately cited.

Research manuscripts reporting large datasets that are deposited in a publicly available database should specify where the data have been deposited and provide the relevant accession numbers. If the accession numbers have not yet been obtained at the time of submission, please state that they will be provided during review. They must be provided prior to publication.

Interventionary studies involving animals or humans, and other studies that require ethical approval, must list the authority that provided approval and the corresponding ethical approval code.

2.1. Study Design

Middle-aged (45 to 75 years), consecutive patients with intermittent claudication (Rutherford 3) and without signs of inflammation, qualified for lower limb percutaneous transluminal angioplasty (PTA) were enrolled. The number of patients included was based on the power and sample size calculations. Detailed clinical characteristics including co-morbidity burden and cardiovascular treatment were gathered at baseline, prior to endovascular procedures. Individuals were followed up at pre-set intervals of 1, 3, 6 and 12 months after discharge. Patient clinical assessment, vascular imaging, endothelial parameters assessment and collection of urine samples were performed at each of those time points.

The primary outcome of the study was to assess the relationship between urinary LTE4 and LTB4 levels and non-invasive measures of endothelial parameters and its functions described below.

2.1.1. Flow-Mediated Dilatation (FMD)

The brachial artery was localized with the use of an ultrasound transducer 2-5 cm above the cubital fossa. The cuff was placed on the forearm and was pumped 50 mm Hg above systolic blood

pressure for 5 min to restrict artery inflow. From 60 s to 90 s after deflation, all vasodilation measurements with vessel diameter changes to reactive hyperemia were made [13]. FMD was measured with the Hitachi Arietta 850 automatic software.

2.1.2. Shear Rate (SR)

The calculation of blood shear force defined as the blood velocity divided by vessel internal diameter. It was assessed during FMD measurement.

2.1.3. Corrected Augmentation Index (AI75)

Represents a backward traveling pressure waves, defined as the ratio of difference in pressure between the early and late systolic shoulders to pulse pressure, reflecting the arterial wall stiffness. In this study we used the standardized index to a heart rate of 75 bpm as it has been proved to be more reliable.

2.1.4. Intima-Media Thickness (IMT)

The measurement of the IMT was conducted in the common carotid artery 1cm proximal to the bulb, on the 10 mm-long part of the far and near wall and calculated by the automatic software provided in Hitachi Arietta 850. The assessment was performed on both sides and the higher result was included in the calculations.

The secondary goal was the evaluation of LTE4 and LTB4 levels and potential associations with clinical characteristics and achievement of a composite endpoint of treated limb-artery restenosis or death at one-year follow-up was performed.

Urine samples were collected at all study visits, centrifuged and stored in a freezer at -80°C until testing. LTE4 and LTB4 were assayed with a competitive Abbexa ELISA kit. The results were recalculated by the concentration of creatinine in urine.

2.2. Ethical Aspects

The study has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans and the proper consent for this study has been obtained from the constituted committee for human subjects or animal research on Jagiellonian University Medical College (1072.6120.365.2020). All of the participants signed the informed consent.

2.3. Statistical Analysis

Continuous variables are summarized as mean (standard deviation) or median (interquartile range). Variable distribution was assessed using QQ plots and the Shapiro-Wilk test. Simple linear regression models were fit for comparison of the relationship between the discussed variables. Skewed variables were transformed to approximate the normal distribution. Right-skewed variables were log-transformed. The decision to include clinically significant covariates in multivariable models was limited due to sample size and the investigators decided, before conducting analyses, that the understanding of the impact of gender and coronary artery disease is theoretically justified.

3. Results

3.1. Characteristics of the Study Population

Out of 126 patients screened, the inclusion criteria were met by 50, who were all enrolled into the study. The participants' mean age of the sample was 65.76 years with a male predominance (66%). The cardiovascular burden of the population was high – 74% had hypertension, 56% previously diagnosed dyslipidemia, 44% documented coronary artery disease, and 44.0% were active smokers. (Supplementary Material, Table S1) During the hospitalization, all patients were treated with

acetylsalicylic acid, clopidogrel, proton pump inhibitors and statins. If necessary, hypotensive drugs were introduced.

3.2. Urinary Leukotriene Levels and Their Relationship with Parameters Reflecting Vascular Function

There was a statistically significant relationship between log-transformed baseline LTB₄ and LTE₄ concentrations. (Supplementary Material, Figure S1)

In univariable analyses, we observed a significant relationship between log-transformed LTB₄ concentration and ultrasound measures reflecting vascular functions and stiffness (Figure 1). A significant univariable relationship between log-transformed LTB₄ levels and flow-mediated dilatation was noted (adjusted R² = 0.47, P<0.001), and was maintained in a multivariable model adjusting for patients' age and sex (adjusted R² = 0.45, P<0.001). Similar observations were noted in univariable baseline analyses for mean IMT (adjusted R²=0.23, P<0.001), AI75 (adjusted R²=0.61, P<0.001) and SR (adjusted R²=0.33, P<0.001). In multivariable models adjusting for the presence of documented coronary artery disease (CAD) and patient sex, we observed LTs to be significant independent predictors of flow-mediated dilatation, arterial augmentation index and vessel wall shear rate. (Supplementary Material, Table S2)




Figure 1. Scatter plot illustrating the relationship between baseline LTB₄ levels and various parameters reflecting vascular arterial function. Blue line represents linear fit, point represent individual measurements (N=50).

In univariable analyses for LTE₄, we observed similar relationships between indirect measures of vascular function and stiffness. A significant univariable relationship between log-transformed LTE₄ levels and flow-mediated dilatation was noted (adjusted R² = 0.69, P<0.001). Similar baseline observations were noted in univariable analyses for mean IMT (adjusted R²=0.12, P<0.01), AI75 (adjusted R²=0.43, P<0.001), SR (adjusted R²=0.48, P<0.001). Similar to LTB₄, no relationship with log-transformed ABI and TBI was noted (P=0.36, P=0.21). (Figure 2)




Figure 2. Scatter plot illustrating the relationship between baseline LTE4 levels and various parameters reflecting vascular arterial function. Blue line represents linear fit, point represent individual measurements (N=50).

3.3. Changes in Urinary Leukotriene Levels and Their Relationship with Alterations in Arterial Function Measures

In univariable analyses, significant relationships were observed between the change in LTE4 and LTB4 levels defined as the change respective to the 1-month as an earliest post-procedural stable assay by 6 months (LT at six months/LT at one month; Δ LT). This time point was chosen as it was the earliest time at which restenosis was reported, which would suggest that sufficient pathological changes within the vascular bed have occurred to be of clinical significance. Analyses were conducted to evaluate whether alterations in LT levels are associated with the progression of arterial function impairment and would aid in the detection of clinical progression with a reference set at earliest pre-procedural assay (Δ FMD, Δ IMT, Δ AI75, Δ SR). Δ LTE4 (adjusted $R^2=0.63$, $P<0.001$) and Δ LTB4 (adjusted $R^2=0.06$, $P=0.047$) were significant predictors of Δ FMD values. Similarly, Δ LTE4 (adjusted $R^2=0.42$, $P<0.001$) and Δ LTB4 (adjusted $R^2=0.29$, $P<0.001$) were significantly related to Δ SR. Δ LTE4 was not associated with Δ AI75 ($P=0.33$), in contrast to Δ LTB4 (adjusted $R^2=0.40$, $P<0.001$). A significant relationship between Δ IMT and Δ LTE4 (adjusted $R^2=0.008$, $P=0.02$), but not Δ LTB4 was noted ($P=0.13$). (Figure 3 and Figure 4)




Figure 3. Scatter plot illustrating the relationships between ΔLTE4 and respective changes in various measures reflecting arterial function and stiffness (1 month to 6 months). Blue line represents linear fit, point represent individual measurements (N=50).




Figure 4. Scatter plot illustrating the relationships between ΔLTB4 and respective changes in various measures reflecting arterial function and stiffness (1 month to 6 months). Blue line represents linear fit, black points represent individual measurements (N=50). Points marked in red represent cases with extreme ΔLTB4 values (the remaining observations have $\Delta\text{LTB4} < 40$ unit/unit). Both patients experienced restenosis by 6 months.

4. Discussion

4.1. The Significance of Leukotrienes in Atherosclerosis

We have previously shown that serial measurements of LTE4 are a useful prognostic factor to aid in the prediction of angioplasty failure [11]. Across studies, urinary LTE4 levels have been treated as a proxy measure of LT generation, and are significantly higher in patients with myocardial infarction, as compared with stable coronary artery disease cases [14]. Aside from LTE4, LTB4 is another candidate biomarker of emerging significance. It is characterized as a potent

chemoattractant, which is produced on-site within vascular lesions and activates immune cell subsets [15]. LTB₄ levels were further tied to luminal carotid diameter in subjects with low arterial oxygen saturation [16]. Taken together, these studies identify an association between processes shaping cardiovascular disease and LTE₄ / LTB₄ generation. The inhibition of leukotrienes pathways is believed to represent a new opportunity in the pharmacological treatment of atherosclerosis [17,18].

A salient finding of the present study is that both LTB₄ and LTE₄ levels share a significant relationship with various indices of vascular function and vessel remodeling. Even though there is clear dependence between those two types of LTs (Supplementary Material, Figure S1) their impact on the individual vascular parameters differs, which may reflect varying involvement in pathobiological processes.

4.2. The Impact of LTs on Vascular Endothelium Parameters

According to the latest suggestions, the thickness of the carotid intima-media layer should not be treated as the marker of subclinical atherosclerosis [19], though it still remains one of the most recognizable cardiovascular disease risk factors [20]. Our results showed that there is a relationship between LTs concentrations and IMT at the baseline, supporting the concept of leukotriene-injured-based endothelium dysfunction theory. The correlation between the change of carotid IMT and LTs level dynamics was not pronounced, which is likely due to the short study timeframe. Furthermore, all patients were treated according to best practices, which include intensive statin therapy, which has been documented to lower the risk of IMT expansion [21].

The relation between arterial wall stiffness and LTs has been the subject of only one in vivo human study so far, and LTB₄ was assayed during only a single time point [22]. Although a causal effect cannot be established by our study due to the presence of potential confounding factors, elevations in LTE₄ and LTB₄ are related to measures of arterial stiffness. (Figure 3C, Figure 4C). As increased arterial stiffness causes the progression of atherosclerosis, we can assume that a sufficient increase in the concentration of leukotrienes may lead to a higher rate of recurrence of lower limb ischemia.

There are multiple factors influencing vascular wall dilatation properties, with a prominent role in inflammation [23]. Our results show that the vascular milieu, represented by increasing values of LTB₄ and LTE₄ is accompanied by impaired vasodilatation. This observation is consistent both prior to and after endovascular treatment, where patients with increased LTs have lower rates of FMD. Moreover, increasing concentrations of LTs were reflected by the further reduction of FMD. (Figure 3A, Figure 4A). Whether a direct pathophysiologic relationship between the reduction of FMD and the development of peripheral artery disease patients exists remains unclear [24].

4.3. Study Limitations

Firstly, the small sample and restenosis count warrant careful consideration of the conclusions drawn at present. While our results are in line with theoretical assumptions that are derived from literature, these findings should be treated as identifying a trend worthy of further evaluation. Although the study sample is moderately heterogeneous in terms of cardiometabolic burden, the recruitment criteria were designed to limit the influence of significant confounders, such as the exclusion of significant renal impairment, which is known to affect urinary LT levels. Last, but not least, the study was conducted only on patients with intermittent claudication, but not with chronic limb-threatening ischemia. This is due the fact that in patients with ischemic wounds concentration of LT will be disturbed by the lower limb inflammation. As the consequence, the conclusions of this study may not be universally adapted for all groups of lower limb ischemia patients.

4.5. Clinical Implications of the Study

To our best knowledge, this is the first prospective study to evaluate the utility of urinary LTB₄ and LTE₄ as surrogate measures of endothelial dysfunction and vascular impairment in patients with moderate-grade peripheral artery disease undergoing endovascular treatment. Over subsequent

follow-up time points, LT levels do not change significantly, which may reflect an individual propensity for “steady state” production. This inherent level of LT generation could reflect the extent and severity of vascular disease, as patients with greater baseline LT levels are at greater risk for restenosis.

This, as well as the fact that both examined LT may significantly induce the recreation of atherosclerotic plaque, supports the existing idea of therapy based on anti-leukotriene drugs [17,25] and significantly contribute to a new pathway of pharmacological treatment development.

5. Conclusions

The findings of the present study show the significant impact of proinflammatory biomarkers represented by LT on the vascular endothelium and its functioning: the vascular inflammation enlarges the thickness of the intima-media complex, increases the vascular wall stiffness and impairs its vasodilatation properties. This is the next step for a hypothetical framework for the utility of leukotrienes as biomarkers of incident restenosis and/or vascular disease progression, but also significantly contributes to a new pathway of pharmacological treatment development for peripheral arterial disease patients.

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org, Figure S1: Scatterplot with line of linear fit illustrating the relationship between urinary LTE4 and LTB4; Table S1: Summary of cardiometabolic co-morbidities of patients at baseline stratified by endpoint status at 12 months. All patients were receiving dual platelet therapy, IPP, and statin at recommended/tolerated dose. No differences in pharmacotherapy were observed apart from more common diuretic use in incident cases (72.7% vs. 35.9%, $P=0.042$); Table S2: Multivariable regression model ($N=50$) for baseline FMD, AI75 and shear rate including leukotriene B4 or E4 levels and co-variables of patient gender and presence of coronary artery disease.

Author Contributions: Conceptualization, Agnieszka Wachsmann-Maga, Piotr Terlecki and Paweł Maga; Data curation, Mikołaj Maga; Formal analysis, Krzysztof Batko; Funding acquisition, Agnieszka Wachsmann-Maga; Investigation, Agnieszka Wachsmann-Maga, Aleksandra Włodarczyk, Mikołaj Maga and Katarzyna Bogucka; Methodology, Agnieszka Wachsmann-Maga, Mikołaj Maga and Paweł Maga; Project administration, Agnieszka Wachsmann-Maga and Mikołaj Maga; Resources, Maria Kapusta; Software, Agnieszka Wachsmann-Maga, Aleksandra Włodarczyk and Mikołaj Maga; Supervision, Piotr Terlecki and Paweł Maga; Validation, Piotr Terlecki and Paweł Maga; Visualization, Agnieszka Wachsmann-Maga and Krzysztof Batko; Writing – original draft, Agnieszka Wachsmann-Maga, Aleksandra Włodarczyk, Mikołaj Maga, Krzysztof Batko, Katarzyna Bogucka and Maria Kapusta; Writing – review & editing, Mikołaj Maga, Piotr Terlecki and Paweł Maga. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Polish National Science Centre with PRELUDIUM, grant number 2017/27/N/NZ5/02191. The APC was funded by Jagiellonian University Medical College.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of Jagiellonian University Medical College Bioethical Committee (1072.6120.365.2020).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Acknowledgments: We would like to thank the Jagiellonian Centre for Experimental Therapeutics JCET for providing us with measurement equipment.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Libby, P. The Changing Landscape of Atherosclerosis. *Nature* 2021, 592, 524–533.
2. Koenig, W. Inflammation Revisited: Atherosclerosis in the Post-CANTOS Era. *Eur. Cardiol. Rev.* **2017**, 12, 89–91, doi:10.15420/ecr.2017:18:1.
3. Fredman, G.; MacNamara, K.C. Atherosclerosis Is a Major Human Killer and Non-Resolving Inflammation Is a Prime Suspect. *Cardiovasc. Res.* 2021, 117, 2563–2574.

4. Russell, K.S.; Yates, D.P.; Kramer, C.M.; Feller, A.; Mahling, P.; Colin, L.; Clough, T.; Wang, T.; LaPerna, L.; Patel, A.; et al. A Randomized, Placebo-Controlled Trial of Canakinumab in Patients with Peripheral Artery Disease. *Vasc. Med. (United Kingdom)* **2019**, *24*, 414–421, doi:10.1177/1358863X19859072.
5. Ridker, P.M.; Everett, B.M.; Thuren, T.; MacFadyen, J.G.; Chang, W.H.; Ballantyne, C.; Fonseca, F.; Nicolau, J.; Koenig, W.; Anker, S.D.; et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N. Engl. J. Med.* **2017**, *377*, 1119–1131, doi:10.1056/nejmoa1707914.
6. Gimbrone, M.A.; García-Cardena, G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. *Circ. Res.* **2016**, *118*, 620–636, doi:10.1161/CIRCRESAHA.115.306301.
7. Ingelsson, E.; Yin, L.; Bäck, M. Nationwide Cohort Study of the Leukotriene Receptor Antagonist Montelukast and Incident or Recurrent Cardiovascular Disease. *J. Allergy Clin. Immunol.* **2012**, *129*, doi:10.1016/j.jaci.2011.11.052.
8. Gaztanaga, J.; Farkouh, M.; Rudd, J.H.F.; Brotz, T.M.; Rosenbaum, D.; Mani, V.; Kerwin, T.C.; Taub, R.; Tardif, J.-C.; Tawakol, A.; et al. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients after an Acute Coronary Syndrome. *Atherosclerosis* **2015**, *240*, 53–60, doi:10.1016/j.atherosclerosis.2015.02.027.
9. Freiberg, J.J.; Tybjaerg-Hansen, A.; Nordestgaard, B.G. Novel Mutations in Leukotriene C4 Synthase and Risk of Cardiovascular Disease Based on Genotypes from 50000 Individuals. *J. Thromb. Haemost.* **2010**, *8*, 1694–1701, doi:10.1111/j.1538-7836.2010.03903.x.
10. Maga, P.; Sanak, M.; Jawien, J.; Rewerska, B.; Maga, M.; Wachsmann, A.; Koziej, M.; Gregorczyk-Maga, I.; Nizankowski, R. 11-Dehydro Thromboxane B2 Levels after Percutaneous Transluminal Angioplasty in Patients with Peripheral Arterial Occlusive Disease during a One Year Follow-up Period. *J. Physiol. Pharmacol.* **2016**, *67*, 377–383.
11. Maga, P.; Sanak, M.; Rewerska, B.; Maga, M.; Jawien, J.; Wachsmann, A.; Rewerski, P.; Szczeklik, W. Urinary Cysteinyl Leukotrienes in One-Year Follow-up of Percutaneous Transluminal Angioplasty for Peripheral Arterial Occlusive Disease. *Atherosclerosis* **2016**, *249*, 174–180, doi:10.1016/j.atherosclerosis.2016.04.013.
12. Wachsmann-Maga, A.; Kaszuba, M.; Maga, M.; Włodarczyk, A.; Krężel, J.; Kaczmarczyk, P.; Bogucka, K.; Maga, P. Leukotrienes in the Atherosclerotic Cardiovascular Diseases – a Systematic Review. *Acta Angiol.* **2022**, *AA4*.
13. Mitchell, A.; Newby, D.E.; Mills, N.L.; Fujisawa, T.; Cruden, N.L.M. Reproducibility of Radial Artery Flow-Mediated Dilatation and Feasibility as a Model of Mechanical Vascular Injury in Man. *Atherosclerosis* **2015**, *241*, e49, doi:10.1016/j.atherosclerosis.2015.04.175.
14. Stodółkiewicz, E.; Rewerska, B.; Rzeszutko, M.; Tomala, M.; Chrustowicz, A.; Zmudka, K.; Sanak, M.; Szczeklik, W. Leukotriene Biosynthesis in Coronary Artery Disease. *Polish Arch. Intern. Med.* **2018**, *128*, 934–942.
15. Riccioni, G.; Bäck, M. Leukotrienes as Modifiers of Preclinical Atherosclerosis? *Sci. World J.* **2012**, *2012*, 1–6, doi:10.1100/2012/490968.
16. Lefebvre, B.; Pépin, J.L.; Baguet, J.P.; Tamisier, R.; Roustit, M.; Riedweg, K.; Bessard, G.; Lévy, P.; Stanke-Labesque, F. Leukotriene B4: Early Mediator of Atherosclerosis in Obstructive Sleep Apnoea? *Eur. Respir. J.* **2008**, *32*, 113–120, doi:10.1183/09031936.00137107.
17. Alomair, B.M.; Al-kuraishy, H.M.; Al-Gareeb, A.I.; Al-Hamash, S.M.; De Waard, M.; Sabatier, J.-M.; Saad, H.M.; El-Saber Batiha, G. Montelukast and Acute Coronary Syndrome: The Endowed Drug. *Pharmaceuticals* **2022**, *15*, 1147, doi:10.3390/ph15091147.
18. Bäck, M.; Yurdagül, A.; Tabas, I.; Öörni, K.; Kovanen, P.T. Inflammation and Its Resolution in Atherosclerosis: Mediators and Therapeutic Opportunities. *Nat. Rev. Cardiol.* **2019**, *16*, 389–406, doi:10.1038/s41569-019-0169-2.
19. Raggi, P.; Stein, J.H. Carotid Intima-Media Thickness Should Not Be Referred to as Subclinical Atherosclerosis: A Recommended Update to the Editorial Policy at Atherosclerosis. *Atherosclerosis* **2020**, *312*, 119–120, doi:10.1016/j.atherosclerosis.2020.09.015.
20. Willeit, P.; Tschiderer, L.; Allara, E.; Reuber, K.; Seekircher, L.; Gao, L.; Liao, X.; Lonn, E.; Gerstein, H.C.; Yusuf, S.; et al. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. *Circulation* **2020**, *142*, 621–642, doi:10.1161/CIRCULATIONAHA.120.046361.
21. Lind, L. Effect of New Statin Treatment on Carotid Artery Intima-Media Thickness: A Real-Life Observational Study over 10 Years. *Atherosclerosis* **2020**, *306*, 6–10, doi:10.1016/j.atherosclerosis.2020.06.012.
22. Labat, C.; Temmar, M.; Nagy, E.; Bean, K.; Brink, C.; Benetos, A.; Bäck, M. Inflammatory Mediators in Saliva Associated with Arterial Stiffness and Subclinical Atherosclerosis. *J. Hypertens.* **2013**, *31*, 2251–2258, doi:10.1097/HJH.0b013e328363dccc.
23. Honda, A.; Tahara, N.; Nitta, Y.; Tahara, A.; Igata, S.; Bekki, M.; Nakamura, T.; Sugiyama, Y.; Kaida, H.;

- Kurata, S.; et al. Vascular Inflammation Evaluated by [¹⁸ F]-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Is Associated With Endothelial Dysfunction. *Arterioscler. Thromb. Vasc. Biol.* **2016**, *36*, 1980–1988, doi:10.1161/ATVBAHA.116.307293.
24. Kaczmarczyk, P.; Maga, P.; Niżankowski, R.; Januszek, R.; Frołow, M.; Maga, M.; Kościelniak, J.; Belowski, A. The Relationship between Pulse Waveform Analysis Indices, Endothelial Function and Clinical Outcomes in Patients with Peripheral Artery Disease Treated Using Percutaneous Transluminal Angioplasty during a One-Year Follow-up Period. *Cardiol. J.* **2020**, *27*, 142–151, doi:10.5603/CJ.a2018.0026.
25. Gautier-Veyret, E.; Bäck, M.; Arnaud, C.; Belaïdi, E.; Tamisier, R.; Lévy, P.; Arnol, N.; Perrin, M.; Pépin, J.-L.; Stanke-Labesque, F. Cysteinyl-Leukotriene Pathway as a New Therapeutic Target for the Treatment of Atherosclerosis Related to Obstructive Sleep Apnea Syndrome. *Pharmacol. Res.* **2018**, *134*, 311–319, doi:10.1016/j.phrs.2018.06.014.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.